National Institute on Aging (NIA)
Chair, Department of Computational Biomedicine,
Cedars-Sinai Medical Center, Los Angeles, California
Email: jhmoore <at> csmc <dot> edu
Artificial intelligence, bioinformatics, biomedical informatics, complex adaptive systems, data science, epistasis, genetic architecture, genetic epidemiology, genomics, human genetics, machine learning, network science, precision medicine, simulation, systems biology, translational bioinformatics, visualization, visual analytics
Distinguished Professor, Department Chair
University of Alabama at Birmingham
Email: austad <at> uab <dot> edu
The long-term goal of my research is to develop treatments to slow the aging process, thus keeping people fit and healthy longer. My laboratory works with different animal species, especially those which are more successful at aging than humans. We work on exotic species, like clams that live more than 500 years, and hydra that don’t age at all, in order to discover such treatments. We also develop measures of laboratory animal health, so that we can assess whether a treatment that makes a mouse live longer also improves the quality of its life. Finally, it has been discovered in recent years that the sexes often respond very differently to treatments than extend life and health. Something that dramatically slows aging in one sex may have no effect on the other sex. We have recently begun exploring why this is so.
Professor of Biotechnology
University of Tartu
Andres <dot> metspalu <at> ut <dot> ee
Dr. Metspalu's major fields of research are genomics and genetic engineering, human genome research methods for large variation in gene banks; genetics and complex diseases, the relationship of genes, environmental factors, lifestyle, and state of health between the molecular and genetic analysis in developing the technology of DNA chip technology.
Founding director of the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
UT Health San Antonio
Email: Suseshad <at> bu <dot> edu
My research focuses on 4 interrelated areas: (a) exploring the correlates of subclinical brain aging including establishing norms for brain MRI and cognitive test performance and relating these measures to novel risk factors (such as visceral fat mass), multiple circulating biomarkers and clinical and subclinical indices of vascular and metabolic disease; (b) the epidemiology of stroke and vascular cognitive impairment including the lifetime risk of stroke, cognitive decline and dementia following stroke, the role of parental stroke and midlife risk factors in determining late-life stroke risk and temporal trends in stroke risk over the past 50 years; (c) the epidemiology of dementia and Alzheimer’s disease (AD) including describing the lifetime risk of AD and relating traditional and novel biomarkers (homocysteine, lipids, diabetes, estrogen, bone mineral density, thyroid function, inflammation) to the risk of dementia and AD.
Associate professor in the Department of Biochemistry and Neurology, Scientific Director of the Emory Integrated Proteomics Core
Email: nseyfriend <at> emory <dot> edu
Research in the Seyfried lab is focused on the integration of proteomics, systems biology, and molecular biology to tackle fundamental questions related to the pathogenesis of Alzheimers Disease (AD) and other neurodegenerative disorders. In particular, his lab utilizes high resolution liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) to identify and quantify proteins and post-translational modifications (PTMs). Combining tools in both molecular and cellular biology, they also explore the relationship between the function of these proteins and their PTMs in the development of these devastating diseases.